EuMentis has completed a Series A to fund development to an IND filing of an NMDA antagonist for ASD, and is conducting a Series B round to fund development of EM-221 through Phase 2. For more information, please contact Mark Tepper (CEO) at:email@example.com
Our unique synthetic approach has many possible applications. We are always looking to capitalize on our team’s talent and experience by acquiring new promising therapies or partnering with like-minded companies or inventors.
EuMentis Therapeutics Inc. Announces Company Launch and Focus on Developing Novel Therapeutics to Treat High Value Neurodevelopmental and Neurodegenerative DiseasesDownload PDF